8-K
filed February 28, 2023, 6:59 PM ET
ticker CMPS
CIK 0001816590
earnings
confidence high
sentiment negative
materiality 0.70
COMPASS Pathways reports FY2022 net loss of $91.5M; Phase 3 psilocybin trials underway
COMPASS Pathways plc
2022-FY EPS reported
-$2.16
- Net loss for FY2022 was $91.5M ($2.16 loss per share) vs $71.7M ($1.79 loss per share) in 2021.
- Cash and cash equivalents fell to $143.2M at Dec 31, 2022 from $273.2M a year earlier.
- Phase 3 pivotal program for COMP360 psilocybin in TRD ongoing; top-line data from trial COMP 005 expected summer 2024.
- R&D expenses increased to $65.1M in FY2022 from $44.0M in FY2021, driven by clinical development.
- FY2023 net cash used in operating activities guided at $85M-$110M; Q1 2023 at $24M-$32M.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
COMPASS Pathways plc reported the three months ended December 31, 2022 results: net income $30.9 million, EPS $0.73 loss per share.
- Period
- the three months ended December 31, 2022
- Net income
- $30.9 million
- EPS
- $0.73 loss per share
- Result
- reported results
Exact text from the filing
Net loss for the three months ended 31 December 2022 was $30.9 million, or $0.73 loss per share
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
COMPASS Pathways plc reported the year ended December 31, 2022 results: net income $91.5 million, EPS $2.16 loss per share.
- Period
- the year ended December 31, 2022
- Net income
- $91.5 million
- EPS
- $2.16 loss per share
- Result
- reported results
Exact text from the filing
Net loss for the year ended 31 December 2022 was $91.5 million, or $2.16 loss per share
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.